Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
11Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
InspireMD, Inc. (NSPR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
22Total relationships
4Distinct source URLs
9High confidence
0.774Average confidence
2026-09-14Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
InspireMD, Inc. Suppliers
Ticker
Name
Confidence
Evidence
APTYX
APTYX
92%
we have engaged Aptyx, a contract manufacturer, to expand our manufacturing capacity of CGuard Prime finished goods to full-scale production at their ISO Class 7 cleanroom facility in North Carolina
BTIG-LLC
BTIG-LLC
92%
Pursuant to the Equity Distribution Agreement, dated April 3, 2026, the Company may offer and sell (the “ Offering ”), from time to time, at its option, through or to BTIG shares of the Company’s com…
PIPER-SANDLER-CO
PIPER-SANDLER-CO
92%
As previously disclosed, on May 31, 2024, the Company entered into that certain equity distribution agreement (the “ Piper EDA ”) with Piper Sandler & Co., as sales agent
Reciprocal relationship from ABT graph: Reciprocal relationship from NSPR graph: fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty…
fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternat…
Reciprocal relationship from BSX graph: Reciprocal relationship from NSPR graph: Reciprocal relationship from BSX graph: Reciprocal relationship from NSPR graph: fficiently or implement changes in cu…
fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternat…
InspireMD, Inc. Customers
Ticker
Name
Confidence
Evidence
CUSTOMER-A
CUSTOMER-A
90%
By principal customers (part of revenues): SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS 2026 2025 Three months ended March 31 2026 2025 Customer A 8 % 16 %
CUSTOMER-B
CUSTOMER-B
90%
By principal customers (part of revenues): SCHEDULE OF REVENUES ATTRIBUTED TO GEOGRAPHIC AREAS BY PRINCIPAL CUSTOMERS 2026 2025 Three months ended March 31 2026 2025 Customer B 9 % 15 %
Reciprocal relationship from ABT graph: Reciprocal relationship from NSPR graph: Reciprocal relationship from ABT graph: Reciprocal relationship from NSPR graph: Reciprocal relationship from ABT grap…
fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternat…
Reciprocal relationship from BSX graph: Reciprocal relationship from NSPR graph: fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty…
fficiently or implement changes in current products in response to design or regulatory requirements; and ● difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternat…
ABBOTT-LABORATORIES-BOSTON-SCIENTIFIC-CORPORATIO
ABBOTT-LABORATORIES-BOSTON-SCIENTIFIC-CORPORATIO
62%
to educate an adequate number of physicians of the benefits of CGuard Prime over alternative treatment options; and 38 ● unforeseen costs and expenses associated with establishing and maintaining an …
BOSTON-SCIENTIFIC-C-R-BARD-INC
BOSTON-SCIENTIFIC-C-R-BARD-INC
62%
our products, if they are approved for sale. The worldwide market for stent products is characterized by intensive development efforts and rapidly advancing technology. Our future success will depend…
HEALTH-RESEARCH-INTERNATIONAL-PERSONAL-MEDICAL-S
HEALTH-RESEARCH-INTERNATIONAL-PERSONAL-MEDICAL-S
62%
ceive adequate reimbursement by governmental and other third-party payers; ● our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be s…
TERUMO-MEDICAL-CORPORATION
TERUMO-MEDICAL-CORPORATION
62%
to educate an adequate number of physicians of the benefits of CGuard Prime over alternative treatment options; and 38 ● unforeseen costs and expenses associated with establishing and maintaining an …
Reciprocal relationship from TMO graph: Reciprocal relationship from NSPR graph: to educate an adequate number of physicians of the benefits of CGuard Prime over alternative treatment options; and 38…
InspireMD, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NSPR-DEBT-11381
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2013-06-30.
NSPR-DEBT-11380
Warrants outstanding: 25828164
90%
xbrl warrant detail from xbrl 2026-03-31.
NSPR-DEBT
Debt stack $3.8M
90%
Market cache reports total debt of $3.8M.
InspireMD, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for InspireMD, Inc..
InspireMD, Inc. Ownership
Holder
Name
Confidence
Evidence
NSPR-OWNER-ROSALIND-ADVISORS-INC
Rosalind Advisors, Inc.
90%
13F overlay lists Rosalind Advisors, Inc. as top holder; 36 tracked holders.
